Stockscreener 앱 받기
26.63
2.99%
-0.82
시간 외 거래:
26.63
전일 마감가:
$27.45
열려 있는:
$27.5
하루 거래량:
2.46M
Relative Volume:
0.61
시가총액:
$4.34B
수익:
$56.99M
순이익/손실:
$-107.23M
주가수익비율:
-32.48
EPS:
-0.8199
순현금흐름:
$-142.55M
1주 성능:
-6.76%
1개월 성능:
-8.55%
6개월 성능:
+127.41%
1년 성능:
+294.52%
1일 변동 폭
$26.25
$27.66
1주일 범위
$26.25
$29.34
52주 변동 폭
$5.595
$34.39
Tango Therapeutics Inc Stock (TNGX) Company Profile
명칭
Tango Therapeutics Inc
전화
(857) 320-4900
주소
201 BROOKLINE AVENUE, BOSTON
Compare TNGX vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
26.63 | 4.34B | 56.99M | -107.23M | -142.55M | -0.8199 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-02 | 개시 | Canaccord Genuity | Buy |
| 2026-02-23 | 개시 | Mizuho | Outperform |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-17 | 개시 | Jefferies | Buy |
| 2024-04-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-02-12 | 개시 | Piper Sandler | Overweight |
| 2023-12-08 | 개시 | B. Riley Securities | Buy |
| 2022-10-20 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | 개시 | SVB Leerink | Outperform |
모두보기
Tango Therapeutics Inc 주식(TNGX)의 최신 뉴스
Tango Therapeutics Inc (TNGX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
TNGX: Tango Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Tango Therapeutics, Inc. (TNGX) stock price, news, quote and history - Yahoo Finance UK
Tango Therapeutics, Inc. (TNGX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Tango Therapeutics Inc (TNGX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48% - Yahoo Finance Singapore
TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside - Stocktwits
Mizuho Raises Price Target on Tango Therapeutics to $40 From $36, Keeps Outperform Rating - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
TNGX Maintained by Mizuho -- Price Target Raised to $40.00 - GuruFocus
Mizuho raises Tango Therapeutics stock price target on combo data - Investing.com
Mizuho raises Tango Therapeutics stock price target on combo data By Investing.com - Investing.com Canada
This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm
JPMorgan initiates Tango Therapeutics stock at Overweight By Investing.com - Investing.com Australia
JPMorgan initiates Tango Therapeutics stock at Overweight - Investing.com UK
Tango Therapeutics (TNGX) to Benefit From Vopimetostat + KRAS Inhibitors Combined Revenues - Yahoo Finance
TNGX Initiates Coverage On JP Morgan -- Rating Set to Overweight - GuruFocus
JPMorgan Initiates Coverage on Tango Therapeutics With Overweight Rating, $46 Price Target - marketscreener.com
J.P. Morgan Initiates Tango Therapeutics(TNGX.US) With Buy Rating, Announces Target Price $46 - Moomoo
Tango Therapeutics Inc (TNGX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Top Hyperliquid Strategies (PURR) Competitors 2026 - MarketBeat
2 Monster Growth Stocks Analysts Think Can Reach New Highs - The Globe and Mail
Does Tango Therapeutics' (TNGX) Russell Growth Shift Reveal Its True Biotech Identity to Institutions? - simplywall.st
Form 4 Tango Therapeutics Inc For: 2 July By Investing.com - Investing.com UK
Tango Therapeutics president Crystal Adam sells $798,908 in stock By Investing.com - Investing.com South Africa
Tango Therapeutics president Crystal Adam sells $798,908 in stock - Investing.com
Tango Therapeutics (TNGX) R&D president exercises options and sells 27,000 shares - Stock Titan
Price to book forward of Tango Therapeutics, Inc. – NASDAQ:TNGX - TradingView
Tango Therapeutics Rides a New Precision Oncology Trend in 2026 - Yahoo Finance
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026? - Yahoo Finance
TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts - Yahoo Finance
TNGX Q1 2026 Earnings: Net Loss Slightly Misses Estimates as Pre-Revenue Biotech Advances PipelineHigh Growth Earnings - dars.gov.et
TNGX Maintained by Canaccord Genuity -- Price Target Raised to $46 - GuruFocus
Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 2500 Growth Benchmark - marketscreener.com
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $46 - Moomoo
Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 2000 Growth Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM:TNGX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 3000E Growth Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) dropped from Russell 3000 Value Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) dropped from Russell 3000E Index - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) dropped from Russell Microcap Index - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) dropped from Russell 2500 Value Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM:TNGX) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 3000 Growth Benchmark - marketscreener.com
Enterprise value to revenue forward of Tango Therapeutics, Inc. – NASDAQ:TNGX - TradingView
Enterprise value to EBITDA forward of Tango Therapeutics, Inc. – NASDAQ:TNGX - TradingView
Jefferies Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Tango Therapeutics Inc (TNGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.46%
0.84%
자본화:
|
볼륨(24시간):